2-[(3S)-3-methylmorpholin-4-yl]ethanol | 1207624-45-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 2-[(3S)-3-methylmorpholin-4-yl]ethanol
• CAS: 1207624-45-0
• 化学式: C₇H₁₅NO₂
• 分子量: 145.202
• InChiKey: QQSZZNXKPVGIMY-ZETCQYMHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  32.7
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted piperidines as therapeutic compounds
  申请人：Speedel Experimenta AG

  公开号：EP2018862A1

  公开（公告）日：2009-01-28

  Described are compounds of the general formula (I) and pharmaceutically acceptable salt thereof, in which R2, R3, W,and X have the definitions illustrated in detail in the description, as beta-secretase, cathepsin D, plasmepsin II and/or HIV protease inhibitors.

  描述了一般式（I）的化合物及其药用可接受的盐，其中R2、R3、W和X的定义在描述中详细说明，作为β-分泌酶、半胱氨酸蛋白酶D、质体蛋白酶II和/或HIV蛋白酶抑制剂。
• IMIDAZOPYRIDIN-2-ONE DERIVATIVES
  申请人：Ohtsuka Masami

  公开号：US20110082138A1

  公开（公告）日：2011-04-07

  A compound represented by formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof.

  具有mTOR抑制活性的公式(I)表示的化合物或其药理可接受的盐。
• PYRIDO-AZAHETERECYDIC COMPOUND AND PREPARATION METHOD AND USE THEREOF
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US20180244667A1

  公开（公告）日：2018-08-30

  The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.

  本发明公开了一种由式I表示的吡啶基-氮杂环化合物，其异构体，其药学上可接受的盐或溶剂，其制备方法以及包含该化合物的组合物，并将其用作多靶点蛋白激酶抑制剂，用于制备治疗与蛋白激酶（尤其是c-Met）相关的疾病的药物，例如癌症等。式I表示的化合物对过表达c-Met激酶的肿瘤细胞具有强大的抑制活性，可以有效靶向c-Met介导的信号通路，并可用于治疗由c-Met激酶过表达引起的癌症等疾病。
• IMIDAZOPYRIDIN-2-ON DERIVATIVE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP2308877A1

  公开（公告）日：2011-04-13

  There is provided a compound represented by the following formula (I) having mTOR inhibitory activity or a pharmacologically acceptable salt thereof. [In the formula (I), A is a 8- to 10-membered partially saturated or aromatic fused bicyclic nitrogen-containing heterocyclic group having 1 to 3 nitrogen atoms, R1 is a hydroxy group, a halogen atom, a cyano group or the like, n is any integer of 0 to 3, B is a 3- to 7-membered monocyclic saturated or partially saturated cyclic hydrocarbon group and may contain 1 or 2 oxygen atoms, sulfur atoms, nitrogen atoms or the like as ring constituents, R2 is a substituent present on a carbon atom or nitrogen atom forming B, m is any integer of 0 to 3, Q is a bond or a C1-4 alkylene group, R3 and R4 are the same or different and are each a hydrogen atom, a halogen atom, a C1-4 alkyl group or the like, and R5 and R6 are the same or different and are each a hydrogen atom, a halogen atom, a C1-4 alkyl group or the like.]

  本发明提供了由下式（I）代表的具有 mTOR 抑制活性的化合物或其药理学上可接受的盐。[在式 (I) 中，A 是具有 1 至 3 个氮原子的 8 至 10 元部分饱和或芳香族融合双环含氮杂环基团，R1 是羟基、卤素原子、氰基或类似基团，n 是 0 至 3 的任意整数，B 是 3 至 7 元单环饱和或部分饱和环烃基团，可含有 1 或 2 个氧原子、硫原子、氮原子或类似基团作为环成分，R2 是取代基、R2 是存在于构成 B 的碳原子或氮原子上的取代基，m 是 0 至 3 的任意整数，Q 是键或 C1-4 亚烷基，R3 和 R4 相同或不同且各自是氢原子、卤素原子、C1-4 烷基或类似基团，R5 和 R6 相同或不同且各自是氢原子、卤素原子、C1-4 烷基或类似基团。]
• Pyrido-azaheterecydic compound and preparation method and use thereof
  申请人：SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

  公开号：US10710996B2

  公开（公告）日：2020-07-14

  The present invention discloses a pyrido-azacyclic compound represented by formula I, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, a preparation process thereof and a composition comprising the compound, and a use thereof as a multi-target protein kinase inhibitor in the preparation of a medicament for the treatment of diseases that are associated with protein kinase, especially c-Met, such as cancer and the like. The compound represented by formula I has potent inhibitory activity on tumor cells with overexpression of c-Met kinase, can effectively target c-Met-mediated signaling pathway, and can be used in the treatment of diseases such as cancer and the like that is caused by the overexpression of c-Met kinase.

  本发明公开了一种式I代表的吡啶-氮杂环化合物、其异构体、其药学上可接受的盐或药学上可接受的溶液、其制备工艺和包含该化合物的组合物，以及其作为多靶点蛋白激酶抑制剂在制备治疗与蛋白激酶，特别是c-Met相关的疾病（如癌症等）的药物中的用途。式 I 所代表的化合物对 c-Met 激酶过表达的肿瘤细胞具有强效抑制活性，可有效靶向 c-Met 介导的信号通路，可用于治疗 c-Met 激酶过表达引起的癌症等疾病。